In glioma, increased TMZ resistance, conferred by the upregulations of risky lncRNAs such as H19, MALAT1, PVT1, and SBF2-AS1 (Figure 1), is likely to play a key role in the therapeutic efficacy of surgical resection plus drug treatment. Here, MALAT1 is linked to central nervous system cancer.